Oncternal Therapeutics to Present at Stifel Virtual Healthcare Conference
Oncternal Therapeutics (Nasdaq: ONCT) will present a company overview at the Stifel Virtual Healthcare Conference on November 16, 2020, at 2:00 p.m. ET. The presentation will be led by Dr. James Breitmeyer, President and CEO. Investors can access the webcast and replay through the Events & Presentations page on the company's website. Oncternal is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies for unmet medical needs. Key candidates include cirmtuzumab and TK216, targeting critical cancer pathways.
- None.
- None.
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Stifel Virtual Healthcare Conference on Monday, November 16, 2020 at 2:00 p.m. ET/ 11:00 a.m. PT.
Webcast Link:
A link to the webcast along with a replay will be accessible on the Events & Presentations page of the Investors section on the Company’s website at https://investor.oncternal.com/news-and-events/events-presentations.
About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at www.oncternal.com.
Oncternal Contacts:
Company Contact
Richard Vincent
858-434-1113
rvincent@oncternal.com
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
FAQ
When will Oncternal present at the Stifel Virtual Healthcare Conference?
Who will present for Oncternal at the conference?
How can I access the Oncternal presentation webcast?
What is Oncternal Therapeutics focused on?
What are the main products in Oncternal's pipeline?
